Mass tort marketing works differently from the local marketing most firms know. A local PI firm wants people in one metro who already know they need a lawyer. A mass tort campaign looks for people across the country who used a specific product, developed a specific injury in a specific window, and in many cases do not yet know a lawsuit exists. Budgets are larger, competition is national, and most of the cost sits in qualifying claimants, not in finding them.
This guide covers where the litigation volume actually is, the channels that reach claimants, how to qualify at scale, and the ethics and advertising rules that apply with extra force to drug and device cases.
Where is the mass tort volume right now?
Start with the official numbers. The Judicial Panel on Multidistrict Litigation publishes a monthly report of every pending MDL. As of its November 2, 2026 report, the dockets with the most pending actions included:
| MDL | Actions pending (Nov. 2, 2026) |
|---|---|
| Johnson & Johnson talcum powder (MDL 2738) | 69,376 |
| Davol / C.R. Bard hernia mesh (MDL 2846) | 23,299 |
| Aqueous film-forming foams (MDL 2873) | 15,270 |
| Hair relaxer (MDL 3060) | 12,743 |
| Proton-pump inhibitors (MDL 2789) | 11,404 |
| Bair Hugger warming devices (MDL 2666) | 8,414 |
| Paraquat (MDL 3004) | 6,635 |
| Depo-Provera (MDL 3140) | 6,413 |
| GLP-1 receptor agonists (MDL 3094) | 4,082 |
The same report shows how concentrated the work is. Of all actions ever filed in currently pending MDLs, 98.24% sit in the 39 dockets with 1,000 or more actions. The Panel’s breakdown by type lists 164 pending MDLs, 65 of them product liability.
Two lessons for marketing. First, a few large dockets attract most of the advertising money, so cost per claimant there is usually highest. Second, not every proposed tort becomes an MDL. In its 2025 calendar year statistics, the Panel reported 32 motions for centralization filed and 21 granted. Marketing a tort before centralization is a bet, and should be budgeted like one.
How is mass tort marketing different from local legal marketing?
- The audience is national, and many potential claimants do not know they were harmed or that litigation exists. Your marketing has to educate before it can convert.
- Qualification is the hard part. A claimant needs proof of use or exposure, a qualifying diagnosis and dates that fit the litigation’s criteria. Interest alone means little.
- Competition is national. You are bidding against large plaintiff firms and specialist lead companies for the same people.
- Advertising rules multiply. A national campaign has to satisfy the rules of every state where it runs, plus statutes aimed specifically at drug and device ads.
Which channels generate mass tort claimants?

| Channel | Strength | Watch out for |
|---|---|---|
| TV and radio | Reach, including older audiences who are less active online | Pays for every viewer; low qualification rate; scripts must meet state drug-ad statutes |
| Google search | People already searching for the drug, device or lawsuit | Clicks on active torts are often very costly; check your own Keyword Planner ranges |
| Facebook and Instagram | Awareness at scale, video, instant forms | Health targeting removed; copy cannot imply the viewer has a condition |
| Programmatic display and video | Cheap reach and retargeting | Lowest intent; fraud and junk inventory |
| Organic content | Long-term traffic on new or niche torts | Slow; hard to outrank news and medical sites on major torts |
| Bought leads | Fast volume | Ethics limits on how vendors are paid; consent and fraud risk |
What has changed on Facebook and Instagram?
Older guides suggest targeting people whose interests or behaviors “correlate with exposure” to a drug. That door is mostly closed. In January 2022 Meta removed detailed targeting options tied to health causes and other sensitive topics. Meta’s personal attributes policy also bars ads that assert or imply a person’s medical condition. Its own examples reject “Do you have diabetes?” and allow “New diabetes treatment available.” So “Did you develop cancer after using X?” is likely to be rejected, while an ad about the litigation itself (“Lawsuits filed over X and cancer: free case review”) is the safer frame. Our Facebook ads guide covers forms and tracking.
Does SEO work for mass torts?
For the largest torts, page one is crowded with news outlets, medical sites and large firms. The realistic organic play is depth on newer torts and narrower questions: qualification criteria, the litigation timeline, what a plaintiff fact sheet asks for, which injuries are being alleged. Content written early, and kept current as the docket moves, can collect traffic later at no media cost. See our law firm SEO guide for the fundamentals.
What advertising rules apply to drug and device ads?

On top of the bar’s general advertising rules, some states have statutes aimed at lawsuit ads about medications and medical devices. West Virginia’s 2020 law is a clear example. A covered ad must include the warning “Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death.” It must say “This is a paid advertisement for legal services,” must disclose whether the drug or device remains FDA-approved (unless it was recalled or withdrawn), and cannot be presented as a “consumer medical alert,” “health alert,” “public service health announcement” or similar. The Fourth Circuit upheld the law in Recht v. Morrisey (2022) against a First Amendment challenge. Check whether any state in your media plan has a similar statute before a spot airs there.
The general rules still apply. Under ABA Model Rule 7.1, as in North Dakota’s version, an ad is misleading if it is likely to create an unjustified expectation about results, so settlement figures and “compensation available” claims need care. Some states require specific disclaimers, filing or pre-approval of ads.
How do you qualify mass tort leads at scale?
Generating leads without qualification is just expensive data collection. A raw lead might have used the product but have no qualifying injury, have the injury but no proof of use, fall outside the relevant dates, already have a lawyer, misunderstand what they responded to, or give false answers to get through a screener. A workable process has stages:
- A short online or phone screener on product, injury and dates.
- A live intake call to confirm details, check for existing counsel and judge credibility. Speed matters here. See our speed to lead guide.
- Proof of use and diagnosis: pharmacy records, medical records, device or lot information.
- Attorney review against the firm’s criteria before the retainer is signed, or before the case is filed.

Each stage costs money and filters people out. Budget on cost per signed and documented claimant, never on cost per raw lead, and track the drop-off at every stage by source so you can see which channel or vendor produces files that survive review.
What ethics rules apply when you buy mass tort leads or partner with other firms?
Most mass tort volume is bought or shared in some way, so the rules on paying for cases matter more here than anywhere else in legal marketing.
- Buying leads. Under ABA Model Rule 7.2(b) and its comment, followed in states such as North Dakota, you may pay a lead generator if it does not recommend you, its communications are not misleading, and the payment is consistent with the fee-sharing rules.
- How vendors are paid. Many mass tort vendors price per “signed” or “retained” claimant. A fee tied to retention can look like sharing legal fees with a nonlawyer, which Rule 5.4(a) prohibits. New York’s Ethics Opinion 1131 approved lead payments that were flat or per lead and unrelated to whether the person retains the lawyer. Get your own state’s answer before agreeing to per-retainer pricing.
- Splitting fees with other firms. Co-counsel and referral arrangements are common in mass torts. Rule 1.5(e) allows a fee division between lawyers in different firms only under conditions, such as division in proportion to work or joint responsibility, the client’s written consent, and a reasonable total fee. North Dakota’s version is one example. States differ on the details.
- Calls and texts. If a vendor calls or texts people for you, Rule 7.3 limits live solicitation, and the TCPA applies. The FCC’s one-to-one consent rule was vacated before it took effect, and the FCC reinstated the prior rule in August 2025. Prior express written consent is still required for autodialed or prerecorded telemarketing calls and texts. Ask every vendor for the consent language and a record for each lead.
Our pay-per-lead guide goes deeper on vendor contracts, exclusivity and the questions to ask before you buy.
What does a mass tort campaign budget include?
| Line item | What it covers |
|---|---|
| Media | TV, radio, search, social and display spend |
| Lead purchases | Third-party leads, if any |
| Intake and screening | Staff or an outsourced call center, scripts, quality review |
| Records | Pharmacy and medical record retrieval and review |
| Technology | CRM, call tracking, e-signature, document collection |
| Compliance | Ad review in every target state, consent records, TCPA review |
The figure that matters is cost per signed, documented claimant for each tort and each source. It will differ widely between a new tort with little competition and a crowded docket, so measure it rather than assume it.
Should you build a mass tort operation or buy one?
Building in house gives you control over messaging, lead quality and compliance, and keeps the data. It also needs media buyers, trained screeners and attorneys who can review files at volume. Buying through vendors or partnering with an established mass tort firm gets you to market faster, but you give up control over quality and pay for the convenience. Many firms run their own campaigns on torts they know well and buy or co-counsel on others.
Whichever route you take, run mass torts as their own business line with their own budget and reporting. The two common failures are underfunding a campaign and quitting before it has enough claimants to matter, and buying raw leads without paying for the screening that turns them into viable files.
To see how we approach this work, read about our mass tort marketing service.
Sources
- Judicial Panel on Multidistrict Litigation, “MDL Statistics Report: Distribution of Pending MDL Dockets by Actions Pending,” November 2026
- Judicial Panel on Multidistrict Litigation, “Pending MDL Dockets by MDL Type,” November 2026
- Judicial Panel on Multidistrict Litigation, “Calendar Year Statistics, January through December 2025,” January 2026
- Meta for Developers, “Updating Meta’s Detailed Targeting Options,” December 2021
- Meta Transparency Center, “Privacy Violations and Personal Attributes,” accessed November 2026
- West Virginia Legislature, “Senate Bill 136: Prevention of Deceptive Lawsuit Advertising and Solicitation Practices Regarding the Use of Medications,” 2020
- U.S. Court of Appeals for the Fourth Circuit, “Recht v. Morrisey, No. 21-1684,” April 2022
- North Dakota Supreme Court, “Rule 7.1 Communications Concerning a Lawyer’s Services” (tracks ABA Model Rule 7.1), accessed November 2026
- North Dakota Supreme Court, “Rule 7.2 Advertising” and comment (tracks ABA Model Rule 7.2), accessed November 2026
- North Dakota Supreme Court, “Rule 5.4 Professional Independence of a Lawyer,” accessed November 2026
- North Dakota Supreme Court, “Rule 1.5 Fees,” accessed November 2026
- New York State Bar Association, “Ethics Opinion 1131,” August 2017
- Federal Communications Commission, “Delete, Delete, Delete; Targeting and Eliminating Unlawful Text Messages,” 90 Fed. Reg. (August 29, 2025)
Want this handled for your firm?
Darkstar runs marketing for law firms end to end: SEO, content, reviews, ads, and call tracking, with a live dashboard so you always know what is working. Book a strategy call.
Book a strategy call →